<?xml version='1.0' encoding='utf-8'?>
<document id="18443385"><sentence text="Effects of etoricoxib on the pharmacokinetics of phenytoin."><entity charOffset="11-21" id="DDI-PubMed.18443385.s1.e0" text="etoricoxib" /><entity charOffset="49-58" id="DDI-PubMed.18443385.s1.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.18443385.s1.e0" e2="DDI-PubMed.18443385.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18443385.s1.e0" e2="DDI-PubMed.18443385.s1.e1" /></sentence><sentence text="Etoricoxib is presently the most commonly prescribed cyclooxygenase-2 (Cox-2) inhibitor for chronic pain and inflammatory conditions"><entity charOffset="0-10" id="DDI-PubMed.18443385.s2.e0" text="Etoricoxib" /></sentence><sentence text=" In clinical practice, phenytoin and etoricoxib are used in chronic conditions of generalized seizure with concomitant chronic pain"><entity charOffset="23-32" id="DDI-PubMed.18443385.s3.e0" text="phenytoin" /><entity charOffset="37-47" id="DDI-PubMed.18443385.s3.e1" text="etoricoxib" /><pair ddi="false" e1="DDI-PubMed.18443385.s3.e0" e2="DDI-PubMed.18443385.s3.e0" /><pair ddi="false" e1="DDI-PubMed.18443385.s3.e0" e2="DDI-PubMed.18443385.s3.e1" /></sentence><sentence text=" Hence, there are chances of drug-drug interaction because modulations of isoenzymes involved in metabolism CYP2C9/10 and CYP2C19 which partially inhibited by etoricoxib"><entity charOffset="159-169" id="DDI-PubMed.18443385.s4.e0" text="etoricoxib" /></sentence><sentence text=" It is important to maintain the therapeutic level of phenytoin in plasma for effective control of seizure"><entity charOffset="54-63" id="DDI-PubMed.18443385.s5.e0" text="phenytoin" /></sentence><sentence text=" So, the aim of the study was to determine the effect of etoricoxib on the pharmacokinetics of phenytoin in rabbits"><entity charOffset="57-67" id="DDI-PubMed.18443385.s6.e0" text="etoricoxib" /><entity charOffset="95-104" id="DDI-PubMed.18443385.s6.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.18443385.s6.e0" e2="DDI-PubMed.18443385.s6.e0" /><pair ddi="false" e1="DDI-PubMed.18443385.s6.e0" e2="DDI-PubMed.18443385.s6.e1" /></sentence><sentence text=" In a parallel design study, phenytoin (30 mg/kg/day) was given daily for seven days"><entity charOffset="29-38" id="DDI-PubMed.18443385.s7.e0" text="phenytoin" /></sentence><sentence text=" On day 7, blood samples were taken at various time intervals between 0-24 h" /><sentence text=" In etoricoxib group, phenytoin was administered for seven days as above"><entity charOffset="4-14" id="DDI-PubMed.18443385.s9.e0" text="etoricoxib" /><entity charOffset="22-31" id="DDI-PubMed.18443385.s9.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.18443385.s9.e0" e2="DDI-PubMed.18443385.s9.e0" /><pair ddi="false" e1="DDI-PubMed.18443385.s9.e0" e2="DDI-PubMed.18443385.s9.e1" /></sentence><sentence text=" On day 8, etoricoxib (5" /><sentence text="6 mg/kg) along with phenytoin (30 mg/kg/day) was administered and blood samples were drawn as above"><entity charOffset="20-29" id="DDI-PubMed.18443385.s11.e0" text="phenytoin" /></sentence><sentence text=" Plasma phenytoin levels were assayed by HPLC and pharmacokinetic parameters were calculated" /><sentence text=" In etoricoxib group, there was a decrease in t(1/2)a phenytoin and t(1/2)el decreased significantly as compared to phenytoin group"><entity charOffset="4-14" id="DDI-PubMed.18443385.s13.e0" text="etoricoxib" /><entity charOffset="54-63" id="DDI-PubMed.18443385.s13.e1" text="phenytoin" /><entity charOffset="116-125" id="DDI-PubMed.18443385.s13.e2" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.18443385.s13.e0" e2="DDI-PubMed.18443385.s13.e0" /><pair ddi="false" e1="DDI-PubMed.18443385.s13.e0" e2="DDI-PubMed.18443385.s13.e1" /><pair ddi="false" e1="DDI-PubMed.18443385.s13.e0" e2="DDI-PubMed.18443385.s13.e2" /><pair ddi="false" e1="DDI-PubMed.18443385.s13.e1" e2="DDI-PubMed.18443385.s13.e1" /><pair ddi="false" e1="DDI-PubMed.18443385.s13.e1" e2="DDI-PubMed.18443385.s13.e2" /></sentence><sentence text=" Significant changes were observed in the pharmacokinetic parameters in etoricoxib-treated group"><entity charOffset="72-82" id="DDI-PubMed.18443385.s14.e0" text="etoricoxib" /></sentence><sentence text=" These results suggest that etoricoxib alters the pharmacokinetics of phenytoin"><entity charOffset="28-38" id="DDI-PubMed.18443385.s15.e0" text="etoricoxib" /><entity charOffset="70-79" id="DDI-PubMed.18443385.s15.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.18443385.s15.e0" e2="DDI-PubMed.18443385.s15.e0" /><pair ddi="false" e1="DDI-PubMed.18443385.s15.e0" e2="DDI-PubMed.18443385.s15.e1" /></sentence><sentence text=" Confirmation of these results in human studies will warrant changes in phenytoin dose or frequency when etoricoxib is co-administered with it"><entity charOffset="105-115" id="DDI-PubMed.18443385.s16.e0" text="etoricoxib" /></sentence><sentence text="" /></document>